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Abstract
In contrast to large GWA studies based on thousands of individuals and large meta-analyses combining GWAS results, we
analyzed a small case/control sample for uric acid nephrolithiasis. Our cohort of closely related individuals is derived from a
small, genetically isolated village in Sardinia, with well-characterized genealogical data linking the extant population up to
the 16
th century. It is expected that the number of risk alleles involved in complex disorders is smaller in isolated founder
populations than in more diverse populations, and the power to detect association with complex traits may be increased
when related, homogeneous affected individuals are selected, as they are more likely to be enriched with and share specific
risk variants than are unrelated, affected individuals from the general population. When related individuals are included in
an association study, correlations among relatives must be accurately taken into account to ensure validity of the results. A
recently proposed association method uses an empirical genotypic covariance matrix estimated from genome-screen data
to allow for additional population structure and cryptic relatedness that may not be captured by the genealogical data. We
apply the method to our data, and we also investigate the properties of the method, as well as other association methods,
in our highly inbred population, as previous applications were to outbred samples. The more promising regions identified in
our initial study in the genetic isolate were then further investigated in an independent sample collected from the Italian
population. Among the loci that showed association in this study, we observed evidence of a possible involvement of the
region encompassing the gene LRRC16A, already associated to serum uric acid levels in a large meta-analysis of 14 GWAS,
suggesting that this locus might lead a pathway for uric acid metabolism that may be involved in gout as well as in
nephrolithiasis.
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Introduction
Nephrolithiasis is a multifactorial disorder of complex etiology
characterized by the presence of stones in the urinary tract.
Kidney stones are a common disorder, with a prevalence of
urinary calculi between 4% and 10% in the adult population, with
an increasing incidence in Western societies [1]. For instance, in
the US the prevalence has risen from 3.2% to 5.2% in just over
two decades from the mid-1970s to the mid-1990s [2]. Wide
geographical variations exist in renal stone incidence and
composition, and specific geographic belts have been identified
[3], where increased incidence has been attributed to genetic and
environmental factors, such as hot climate (fluid loss) and sun
exposure that increases the rate of vitamin D.
Kidney stones are composed of inorganic and organic crystals
amalgamated with proteins. Crystallisation and subsequent
lithogenesis can happen with many solutes in the urine.
Calcareous stones are still by far the most common type of
nephrolithiasis, accounting for more than 80% of stones [4]. Uric
acid nephrolithiasis (UAN) represent about 5–10% of the
remaining stones, trailed by cystine, struvite, and ammonium acid
urate stones.
Genetic contribution to renal stones formation has been
extensively recognized, and a number of studies have established
a link between several genes and predominantly oxalate kidney
stones, including vitamin-D receptor gene (VDR) and calcitonin
receptor (CTR) gene, heparan sulfate (HSPG2) gene, and
fibronectin gene (FN1) [5,6]. There are a number of factors that
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obesity, specific drugs, other diseases, climate changes, metabolic
disorders, and genetic predisposition [7,8]. The complexity of this
disease has led researchers to consider nephrolithiasis as one
feature of a broader systemic disease, rather than a disease specific
to a single organic system. This is especially interesting in relation
to gout and metabolic syndrome, which are both systemic
disorders in close relation with nephrolithiasis [9,10]. UAN
primarily results from low urinary pH, which increases the
concentration of the insoluble undissociated uric acid, causing
formation of both uric acid and mixed uric acid/calcium oxalate
stones. A persistently low urinary pH (,5.5, the pKa for uric acid
is 5.35) is a distinctive feature of idiopathic UAN previously named
gouty diathesis [11].
In this study we focused on a Sardinian isolated population, the
village of Talana, located in a mountain area of the island. The
Talana population has been extensively studied, and has been
characterized by a limited number of original founders, a long-
term, slow population growth rate and isolation [12,13]. Studying
founder, isolated populations like the Talana, allows to reduce
genetic complexity underlying disease etiology and to increase
environmental homogeneity, as inhabitants share a common and
uniform lifestyle. In the extant population of Talana the frequency
of nephrolithiasis is approximately 20%, with a strong prevalence
of UAN stones (half of all renal stone formers). In our previous
study, we performed a genome-wide linkage search in 14 closely-
related affected individuals using 382 microsatellites. Suggestive
regions were investigated in 37 individuals who were more
distantly-related affecteds [14], allowing us to fine-map a
susceptibility locus on the chromosomal region 10q21–q22, and
to identify a possible candidate gene [15].
The advent of high-throughput technologies for single nucleo-
tide polymorphisms (SNPs) genotyping has allowed for a rapid and
an economical way to do GWA analysis, and it might now be
possible to achieve adequate power for identifying risk variants
associated to complex diseases such as nephrolithiasis. In this new
study we perform a GWA scan in a larger sample of well
characterized cases and controls from Talana, utilizing a highly-
dense SNPs map. Association analysis of our cohort of cases and
controls, all related through multiple lines of descent and
belonging to a single, large, and well-characterized genealogy, is
particularly challenging, due to the complex relatedness in the
sample. A number of methods have been proposed in the recent
years for case-control association testing in samples that include
related individuals from a single population provided that the
pedigrees are completely specified [16–19]. It is well known that in
association studies, spurious association can arise if ancestry
differences among the cases and controls are not properly
accounted for. An improved association method, named ROAD-
TRIPS, for samples with related individuals and population
structure, has recently been implemented in a software program
[20]. ROADTRIPS uses an empirical genotypic covariance
matrix calculated from genome-screen data to allow for population
structure and cryptic relatedness in a sample that may not be
captured by the available genealogical information. This method is
appropriate for sampled individuals (both cases and controls) from
a founder population, who are related through multiple lines of
descent, with pedigrees only partially specified. In simulation
studies with related individuals from outbred populations and
population structure, including admixture, ROADTRIPS has
been demonstrated to provide a substantial improvement over a
number of existing methods in terms of power and type 1 error.
Furthermore, in a recent review investigating the current
progresses on methods that correct for stratification while
accounting for additional complexities, ROADTRIPS has been
shown to have appropriate characteristics [21].
We applied ROADTRIPS to a sample of related cases, affected
by UAN, and a sample of unaffected controls selected from the
same isolated population, all related through a complex genealogy.
We also investigated the properties of ROADTRIPS, as well as
other association methods, in our highly inbred population. To
our knowledge this is the first application of this recent method to
a case/control sample of closely related individuals from a founder
population with extended genealogical data. We then followed up
on the more promising regions and the top associated SNPs
identified in our initial sample from the genetic isolate and
performed an association analysis in an independent sample
collected from the Italian population (including a general
Sardinian sub-sample).
Methods
Subjects
The study subjects were 861 individuals from Talana, linked
through a multi-generation 4446-member pedigree, with a mean
(median) kinship coefficient of 0.0201 (0.0115) (SD=0.0231).
During physical examination of each individual, a blood sample
was collected for DNA extraction, and different phenotypic traits,
and pathologies, were recorded. For this study, we collected
information on age at diagnosis, medications, hospital admissions,
and family history. Individuals with a history of urinary tract
infection or with any secondary condition that might predispose to
kidney stones (e.g., inflammatory bowel disease or gout) were not
included. The diagnostic procedures have been carried out
essentially as described elsewhere [14]. In brief, all subjects
affected by renal stones and their family members underwent renal
ultrasound examination to confirm reported disease occurrence
and to identify asymptomatic cases. Clinical renal ultrasonography
is used to image calculi, such as UAS, that are non-opaque on X-
rays [22].
From an initial set of 173 renal stone formers, we selected 80
severe cases that showed uric acid as the principal component.
Author Summary
There are a number of factors that contribute to renal
stone formation, including diet and obesity, specific drugs,
other diseases, climate changes, metabolic disorders, and
genetic predisposition. In this article, we focus on
identifying genomic regions that may be involved with
nephrolithiasis associated with a uric acid component. We
analyze data from a genetic isolate in Sardinia to take
advantage of the potential improvement in power to
detect association with complex traits when related,
homogeneous affected individuals are selected. To take
into account the correlations among our related sample of
cases and controls, we applied a recently proposed
method that corrects for both known and unknown
population and pedigree structure using genome-wide
data. In simulation studies for outbred populations with
related individuals and population structure, the method
has been demonstrated to provide a substantial improve-
ment over a number of existing methods in terms of
power and type 1 error. We investigate the properties of
this new method, as well as other association methods, in
our inbred sample. To our knowledge, this is the first
application of this recently proposed method to a founder
population. This study is also the first genome-wide
association study carried out for uric acid nephrolithiasis.
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stones during ultrasonography and past history of kidney stones,
with more than one episode of abdominal colic. Subjects with mild
to moderate disease symptoms (e.g., having only a single episode
or spots but no episodes) were not classified as affected in the
present study. We identified 94 control subjects, who were
examined by ultrasonography to exclude individuals with
asymptomatic disease. The mean age at observation of unaffected
controls was sufficiently high (,55 years) to have given an elevated
probability of developing stones.
All subjects gave written informed consent, and all samples were
taken in accordance with the Helsinki declaration.
Genotyping
Genotyping for the initial GWA study was carried out using the
Affymetrix 500K chips using standard protocols, and the 50K
chips with SNPs distributed around known genes. SNPs
genotyping was performed on the Affymetrix Gene-Chip platform.
We used the GeneChip Human Mapping to genotype the 500K
Array Set that comprises two arrays (the Nsp and Sty arrays)
capable of genotyping ,262,000 and ,238,000 SNPs, respec-
tively. We followed the recommended protocol described in the
Affymetrix manual. In total, 861 individuals were genotyped for
the 500K set and 528 individuals for the 50K set.
Genotypic quality control
Details on QC analysis in Talana are provided in the Text S1.
Briefly, we first checked for gender mismatches to make sure that
individuals in our database align with individual DNA samples in
the genetic data, dropping problematic samples. Individuals with a
missing rate .90% were removed, and SNPs showing a missing
rate .95% and a MAF ,0.05 were dropped in both the 50K and
500K sample sets. HWE was tested and two different thresholds
(due to the different number of SNPs) were used to exclude SNPs
that showed extreme deviation from HWE (threshold of p,1E-6
for the 500K, and of p,1E-4 for the 50K). Furthermore, we
estimated the proportion of IBD sharing derived from the genome
between each pair of genotyped individuals and compared it with
the proportion expected based on the genealogical information.
Relatedness between examinees was estimated from an LD-
pruned dataset of SNPs derived from the whole genome data using
PLINK [23]. From this analysis we identified and excluded
individuals that showed recurrent inconsistencies between the two
IBD sharing proportions.
Statistical analysis
For the statistical analysis of our sample of related cases and
controls derived from a single large genealogy, we used the
recently proposed method implemented in the ROADTRIPS
software [20]. This program allows for single SNP (currently just
for autosomes) case-control association testing in samples from
isolated founder populations with partially or completely unknown
genealogies. A significant improvement over the previously
proposed tests for founder populations, implemented in the CC-
QLS and the MQLS software packages [16,18], is that ROAD-
TRIPS uses an empirical covariance matrix, denoted by Y,
calculated from genome-wide SNP data to correct for unknown
population and pedigree structure, while maintaining high power
by taking advantage of known pedigree information when it is
available. The structure matrix estimated from genome-wide data
is used in the variance calculation to account for structure that
may not be captured by the kinship coefficient matrix, denoted by
W, derived from the known genealogy. Additional advantages of
this approach are that it allows for two different types of controls,
unaffected controls and controls of unknown phenotype (e.g.,
general population controls), to be included in the same analysis,
and it can incorporate phenotype information on relatives with
missing genotype data at the SNP being tested.
We now give a brief overview of the different test statistics used
in the analysis. The ROADTRIPS extension of the statistics
implemented in the MQLS software, namely, MQLS, WQLS, and
the corrected Pearson’s x
2 test, are RM, RW, and Rx, respectively.
The MQLS, WQLS, and the corrected Pearson’s x
2 tests were
developed for related samples from a single population with known
pedigrees, and ROADTRIPS extends these statistics to allow for
population structure and pedigrees that are partially or completely
unknown. For two-allele disease models, optimal properties of the
MQLS test (and the RM test when the individuals are from a single
population) is that it is most powerful in a general class of linear
statistics for general two-allele disease models in outbreds and for
additive disease models in inbreds, as effect size tends to 0. The
MQLS and RM tests improve power by taking advantage of the
enrichment of predisposing alleles in affected individuals with
affected relatives. The WQLS (and the RW test when the individuals
are from a single population) is optimal when the true genetic trait
model is a rare, fully penetrant dominant allele. The corrected
Pearson’s x
2 test and Rx are extensions of the Pearson’s x
2 test for
independence of trait value and marker genotype. The Rx statistic
has a correction factor that is similar to the correction factor used
in genomic control [24]. When the aforementioned test statistics
have been applied to various association studies in the context of
complex trait mapping, where the traits of interest are influenced
by numerous genes as well as environmental factors, the tests have
given complimentary as well different results, with the MQLS (and
RM) test often having slightly higher power to detect association
than the corrected Pearson’s x
2 test (and Rx) and with WQLS (and
RW) having the lowest power [16,18,20]. A summary of the
characteristics of the statistics that were used is shown in Table 1.
Table 1. Summary of the test statistics used in the analysis.
Test statistic Population controls Corrected for Y Corrected for W Program
RM 333ROADTRIPS
Rx 737ROADTRIPS
RW 733ROADTRIPS
MQLS 373MQLS
Corrected x
2 773MQLS
WQLS 773CC-QLS
doi:10.1371/journal.pgen.1001281.t001
GWAS for Nephrolithiasis
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are based on a x
2 asymptotic null distribution with 1 degree of
freedom. To assess whether or not the p-value is ‘‘exact’’, the
ROADTRIPS software uses a similar criterion to what is
commonly used for Pearson’s x
2 test for independence between
trait and marker genotype, where the expected counts in each cell
for a 262 table should be at least 5 in order for the x
2 distribution
assumption to hold. The asymptotic null distribution assumption
will hold for SNPs with rare alleles provided that there are enough
minor allele counts observed for the SNPs in the sample. The
ROADTRIPS software provides a warning message ‘‘The p-value
might not be exact because of the small number of type 1 alleles in …’’
referring to cases, controls, or both, when the asymptotic null
distribution assumption for the statistics may not be satisfied,
which can occur for SNPs with low minor allele counts.
The Rx test is calculated using naı ¨ve allele frequency estimates,
i.e., allele frequency estimates based on giving equal weights to the
sample individuals, while both the RM, and RW tests use BLUE
estimates [25]. The latter allele frequency estimator is the best
linear unbiased estimator and is calculated conditioned on the
genealogy of the sample individuals. The BLUE takes into account
relatedness in the sample and the estimator allows for inbreeding
and for sample individuals to be related through multiple lines of
descent.
Replication study
We collected an independent sample from the Italian general
population, and in particular 69 cases from the Department of
Nephrology and Dialysis of Bergamo, and 98 controls deriving
from randomly ascertained blood donors in the same area. We
also collected 56 affected individuals, and 59 controls from
randomly ascertained blood donors in Sardinia. The Sardinian
affected individuals were collected from the Clinics of Urology of
Cagliari and Lanusei. All cases were selected to have pure uric acid
stones or uric acid as the principal component. In total we
analyzed 282 individuals (125 cases and 157 controls) in the
replication study, but we considered the two population samples
(continental Italy and Sardinia) as two different clusters, in order to
exclude potential bias in the analysis derived from the geograph-
ical origin of the samples.
We genotyped 96 SNPs in the independent replication sample
as well as in the 73 cases and 93 controls from Talana analyzed in
the initial study. A total of 28 SNPs were selected either from the
top results in the initial study (10 SNPs), or in the candidate
regions on chromosomes 2, 6 and 10, based on a Rx p-value ,0.05
and RM p-value,0.01 (18 SNPs). For 11 out of 28 of these SNPs,
only 48 cases and 67 controls were genotyped in the initial set (i.e.
these SNPs belonged to the 50K set). We also genotyped 4 cSNPs
(missense) in the candidate genes SLC17A1, ADAMTS14, and
UNC5B, selected from Hapmap with a MAF in CEU .0.01. The
remaining SNPs (64) were selected using Tagger [26] to cover the
candidate regions on chromosomes 2, 6 and 10. We selected
tSNPs with the criteria of ‘‘pick only the N best tags’’, where N was
based on the specific size and recombination pattern of each
region. We used the ‘‘pairwise tagging only’’ mode, providing the
Illumina design score for preferential picking of the tSNPs, to
capture only SNPs with MAF.0.05. The tagged regions and the
resulting coverage based on r
2 are shown in Table S1. The initial
set of cases and controls from Talana was also genotyped for the
SNPs typed in the replication cohort.
SNPs were typed by using the VeraCode GoldenGate
Genotyping Assay from Illumina according to the manufacturer’s
protocol (Illumina, San Diego, CA). Briefly, the technology is
based on allele-specific primer extension. Genomic DNA (250 ng)
was activated chemically with biotin and then hybridized to a pool
of locus-specific oligos (OPA, OligoPool All; Illumina). After
removal of nonspecific unbound oligos, a PCR reaction was
performed by using fluorescent-labeled primers (Cy3 and Cy5).
PCR products were cleaned and denatured, and single-stranded
fluorescent-labeled DNAs were hybridized to VeraCode beads,
which were scanned on a BeadXpress reader by using Illumina
VeraScan V1.1 software. Raw data, consisting of intensities of
fluorescence, were then imported into the analysis software
GenomeStudio and the automatic allele calling was done using
GeneCall threshold of 0.25. The final SNP call rate (the number of
SNP successfully genotyped for each sample) was .0.97. Standard
QC was performed and only 1 SNP was excluded due to extreme
deviation from HWE, where this SNP had only the two
homozygous genotypes.
For the replication set, the sample of unrelated cases and
controls was analyzed with PLINK using standard methods, based
on allele frequencies differences. The Cochran-Mantel-Haenszel
(CMH) tests for stratified tables, which allow for tests of association
conditional on cluster of samples was used for merged sets (we
clustered individuals based on the geographic origins, namely
continental Italy and Sardinia). The Breslow-Day (BD) test was
computed to test the homogeneity of odds ratios within clusters.
We also performed a global association test by including to the
replication set a Talana sub-sample that consisted of distantly
related cases/controls, as an additional cluster using the CMH and
BD tests. The Talana sub-sample was extracted from the whole
sample of cases and controls using a pairwise sampling approach
[27] basing on a kinship,0.125 between each pair (resulting in 41
cases and 38 controls).
The 73 cases and 93 controls from Talana, used in the initial
study, were all typed for the 96 SNPs and analyzed with
ROADTRIPS. For 11 SNPs identified in the initial study (28
SNPs), only 48 cases and 67 controls were genotyped in the initial
set (i.e. these SNPs belonged to the 50K set), and the remaining 66
tSNPs were not typed in the initial GWAS. It should also be noted
that for these SNPs we could not use the option in ROADTRIPS
to include all unknown population controls in the analysis as was
done in the initial GWAS, since only cases and unaffected controls
were typed for these SNPs, while the remaining 668 sample
individuals from Talana were not. This smaller sample size can
lead to a reduction in power for the replication analysis, since
samples sizes strongly influence the power of the test.
Results
Evaluation of the test statistics’ properties
For SNPs that have a low minor allele count in either the cases
or the controls (unaffected and unknown phenotype) such that the
asymptotic x
2 null distribution assumption with 1 degree of
freedom for the statistics may not be valid, ROADTRIPS provides
a warning message. In our GWAS we observed 22,502 warning
messages for RM (,7% of the tests), and 26,772 for Rx (,8% of the
tests). We investigated the occurrences of warning messages for the
RM and Rx statistics in relation to MAF. Since in our GWAS we
used all available information, thus also including in the analysis
668 unknown population controls, the RM statistics did not show
any warning message referring to controls, but only to cases. In
Figure S1 we show box-plots of MAF (naı ¨ve estimates) for the RM
and Rx statistics tagged by a warning message for each specific
group (for RM in controls only; for Rx in cases, controls, or both),
stratified by the 500K and 50K sets as a different number of
individuals were genotyped in the two sets (829 and 514 subjects,
respectively).
GWAS for Nephrolithiasis
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stratified by the presence of a warning message in the ROAD-
TRIPS output. This figure illustrates that the asymptotic null
distribution assumption does not hold for SNPs with low minor
allele frequency and counts in our sample (due to the small sample
size used in this analysis), particularly for the RM statistic. We also
investigated whether the lower minor allele count SNPs are
contributing to the excess of smaller p-values of the RM and Rx
statistics than what is expected under the null. From the figure it is
evident that for RM these SNPs do not contribute to any inflation
Figure 1. Q-Q plots for the different test statistics used in the analyses. Q-Q plots are stratified by the naı ¨ve allele frequencies observed in
the whole dataset. Namely, MAF.=0.1 (green points) or MAF,0.1 (blue points).
doi:10.1371/journal.pgen.1001281.g001
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the RM test are anywhere near the significance level threshold, and
for the Rx test the vast majority of the SNPs with warning messages
are also not close to being significant.
Q-Q plots for the different statistics (RM, Rx, RW, MQLS,
corrected x
2 and WQLS) obtained from the GWAs are shown in
Figure 1, where we stratified by naı ¨ve allele frequencies of the
SNPs in the whole sample. From Figure 1, it is clear that for the
SNPs with lower minor allele frequency, the type 1 error
distribution is in general inflated for all statistics based on the
BLUE estimation. In particular, the RM test may be quite sensitive
to allele frequencies, and therefore hard to calibrate. Figure 1 also
illustrates that for SNPs with a minor allele frequency of at least
0.1 the asymptotic null distribution assumption for the RM test
appears to be adequate for this sample, and the test may actually
be conservative for this particular sample in the right tail of the
distribution based on the 2log(p-values), which may result in a
slight loss of power for the RM test for the analysis of this sample.
It is evident that ROADTRIPS provides a significant
improvement of the RM test over MQLS test in this dataset, in
terms of type 1 error, since there appears to be cryptic relatedness
in this study that is not being accounted for in the MQLS statistic,
and for which inflated p-values are observed over the whole
genome (independently from MAF). In contrast, not much
difference is observed between Rx (which corrects for both
population and pedigree structure using genome-wide data) and
the corrected x
2 implemented in MQLS (which corrects for
relatedness using the genealogical data) in our data.
Finally, we were interested in gaining a better understanding
for why some of the SNPs give large p-value differences for the
RM and Rx statistics in our data. We investigated SNPs with
discordant RM and Rx results for the analyses that included the
Table 2. Inbreeding and kinship of the case/control sample used in this analysis.
Inbreeding Kinship
sample
size
pedigree
size
a Median Mean SD Min Max Median Mean SD Min Max
affected
subjects
73 1666 0.0092 0.0095 0.0058 0.00004 0.0316 0.0187 0.0242 0.0285 0.00034 0.2783
control
subjects
92 2341 0.0082 0.0091 0.0070 0.00054 0.0371 0.0163 0.0223 0.0293 0.00001 0.2916
aPedigree connecting all subjects (all affected and all unaffected, separately).
doi:10.1371/journal.pgen.1001281.t002
Figure 2. Manhattan plot for the Rx statistic. Orange points above the 2log10(p-value).4 threshold indicate SNPs that have a p-value,1E-2 for
the RM statistic. Significant threshold after Bonferroni correction is shown.
doi:10.1371/journal.pgen.1001281.g002
GWAS for Nephrolithiasis
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PLoS Genetics | www.plosgenetics.org 8 January 2011 | Volume 7 | Issue 1 | e1001281unknown population controls. Specifically we investigated SNPs
for which the RM test gives a p-value ,1E-4 and the Rx p-value is
not close to significance level (.0.05), and vice versa. In the Text
S2 we present a formal investigation of the different behavior of
the test statistics for the specific SNPs. The large difference that is
observed for RM and Rx for these SNPs is due to the small
number of founders and the high degree of relatedness among the
sample individuals. Even though there are 842 individuals in the
sample, when comparing the allele frequency variance of the
BLUE for this sample to the number of independent (i.e.,
unrelated non-inbred) individuals that would give the same
variance, we estimate the number of independent alleles in the
sample [28] to be equivalent to having approximately 61
founders in the sample, i.e., 61 independent individuals (60.52
to be more precise). This estimate is based on the kinship and
inbreeding coefficients for the 842 individuals that were
calculated from the available genealogical data. The number of
independent alleles in this sample may actually be less than our
estimate since there is evidence of cryptic relatedness in this
sample, as we previously mentioned.
Based on the more stable characteristics of the Rx statistics that
we observed in our sample over the entire range of minor allele
counts (low to high), we focused on results obtained with the Rx
statistics (p-value,1E-4), but we also required validation of the
SNPs by the RM statistic with a p-value ,1E-2. We therefore
included in our follow up analysis potentially interesting SNPs with
small p-values that did not necessarily reach the conservative
Bonferroni genome-wide significance threshold.
GWAS in the initial set
The final SNPs dataset used in this study consisted of a 334,674
SNPs in the merged set (500K and 50K) on the autosomes. The
final sample set, that passed the QC, consisted of 73 affected and
92 controls. The characteristics of the case/control sample used in
this analysis are summarized in Table 2. The 73 affected subjects
are all related through a large pedigree of 1666 individuals. In
total 80 cases and 94 controls were analyzed with ROADTRIPS,
which allows additional phenotyped relatives that are not
genotyped (namely 7 cases and 2 controls) to contribute to the
analysis.
Results from the GWAS for Rx, are shown in Figure 2, where
consistent results obtained with the RM statistics are also
highlighted (RM p-value,1E-2). In Table 3 we summarize the
top results obtained for SNPs that have a Rx p-value,1E-4 and
RM p-value,1E-2.
On chromosome 2p, different SNPs in LD which each other
showed Rx below the 1E-4 threshold. These SNPs and the top
SNP (rs11125301) are located in introns of the NRXN1 gene.
Two other SNPs at different locations on 2q, rs1864466 and
rs2359681, were identified with both Rx and RM. The former,
rs1864466, located in the 39 of the ALS2CR8 gene, and the latter,
rs2359681, is located in an intron of DYTN, and it is in LD with
other SNPs located in the nearby ADAM23 gene, for which
suggestive association is observed with the Rx test (p-val-
ue=0.00018, Figure 3 and Table S2).
On 6p three SNPs were associated with a Rx p-value,1E-4, but
only one, rs10946741, had also a RM p-value ,1E-2 (p-
value=0.00026). Other SNPs in the region and in LD with
rs10946741 showed marginal association. The highest association
is found in a region near the 59 of the LRRC16A gene, found to be
associated in a large meta-analysis with serum uric acid levels [29],
although different SNPs located in introns of LRRC16A or in
introns in flanking genes (SLC17A4 and SLC17A1) showed
association with either the Rx or the RM statistics (Figure 3 and
Table S3). Evidence of association through the RM test was
observed at different SNPs located in introns of LRRC16A, and at
SLC17A4, where a nonsense SNP provided a p-value=0.00354.
Strong LD is observed at SNPs in the SLC17A2 gene, but no
evidence of association is observed with any of the test statistics.
On chromosome 8, the Rx test resulted in the most significant p-
value, 8.95E-08 over the genome (genome-wide significant after
Bonferroni correction, p-value corrected=0.03), at rs12707927.
The closest gene to rs12707927, PVT1, lies 90kb upstream, and
neighbouring SNPs located within the gene were only showing
marginal significance. Also, this SNP was tagged by a warning
message that the minor allele count was small, and as a result the
p-value, which is calculated based on a null distribution
assumption of a x
2 with 1 degree of freedom, may not be exact.
Indeed the allele frequency estimated with the BLUE was 0.082 in
cases and 0.038 in controls for the A allele (allele frequency is
0.062 in Hapmap-CEU). Note that this SNP was not removed in
the QC stage because the estimated naı ¨ve allele frequency was
0.054, and therefore slightly above the set MAF threshold of 5%.
In a region on 10q, three SNPs in strong LD showed association
(rs12784847, rs3740434, and rs11591930) in all statistics, with a
lowest Rx p-value of 0.00003 at rs11591930 (Figure 3 and Table
S4). One of this SNP, rs12784847, is located in an intron of the
ADAMTS14 gene. Further, different SNPs in LD with rs11591930,
and located either in introns or in the 59UTR of the gene showed
nominal association (Rx p-value,0.05), and one SNP (rs10999500)
was a synonymous coding variant of the gene. Further, rs11591930 is
tagging additional SNPs located in introns of the LRRC20 gene
which showed marginal association (best Rx p-value=0.00469,
and RM p-value=0.00552), and in introns of the UNC5B gene
(best Rx p-value=0.00116, and RM p-value=0.00034).
Finally, a SNP located on chromosome 22, rs12167903, was a
missense variant of the CCDC157 gene. ROADTRIPS gave the
warning that Rx p-value might not be correct because of the low
MAF (which is 0.024 in the whole sample estimated by BLUE).
This variant is indeed rare in the literature (2%), and resulted in a
BLUE estimated frequency in our cases of 0.125 (SD=0.060).
Other regions identified in the initial GWAS did not contain
genes with a direct role in stones formation or were regions devoid
of known genes. These regions were not examined further adding
tSNPs in the replication set, but only the top SNPs obtained in the
initial GWAS were typed in the independent sample.
Case-controls study in the replication set
The results of the analysis carried out for the 96 SNPs in the
continental Italian, Sardinian, and merged sets (for a total of 282
Figure3.RegionalassociationplotsfortheRx test.SNAPplots[45]forRxshowthestrengthofassociation,2log10(p-values),versus chromosomal
position (kb) for all SNPs across 1 Mb regions. P-values are plotted with diamonds for all SNPs, shaded white to red by the degree of LD (r
2; see inset),
estimated from the Talana sample, with the associated SNP (larger red diamond). Talana specific linkage disequilibrium (LD) between SNPs was
computed using Haploview [46] from 179 more distantly related individuals selected from the whole sample of genotyped subjects, so that the kinship
between anypairsofindividuals did not exceed0.125.LocalrecombinationratesestimatedfromHapMapCEU(cM/Mb, blue line) areplotted againstthe
secondary y axis, showing recombination hotspots across the region. Labeled green arrows below the plots indicate genes and their orientations.
doi:10.1371/journal.pgen.1001281.g003
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When considering the Sardinian and the continental Italian
sample separately and merged together, using the CMH tests
allowing for two strata, we observed association to UAN in the
chromosome 2 and 6 regions.
In the replication set on 2q33.3 no significant association was
observed when considering the merged sample, but nominal
significance was obtained at three different SNPs in the
continental Italian sample. The SNPs are located in the introns
of ADAM23, with the highest evidence at rs11891267 (p-
value=0.02732). The same SNPs were also found to be associated
in the Talana sample, but the allele frequencies were oppositely
distributed in cases and controls. In the whole Talana sample
(Table S5) two SNPs intronic to ADAM23 (rs1025077 and
rs3755224, Rx p-value=0.01884, and Rx p-value=0.00069,
respectively), and a SNP in the intron region of DYTN
(rs2163033, Rx p-value=0.00818) were additionally found to be
associated to UAN.
In the region encompassing the LRRC16 gene on 6p22.2–p21.3,
different SNPs showed marginal significance in the upstream
region of the gene with peak evidence at rs12665174 with a CMH
p-value of 0.00146. One SNP (rs2149228) located in the intronic
region of the gene also showed nominal significance in the merged
replication set. All the SNPs but rs10946741 (identified in the
initial study and not found significant in the replication set, i.e.
CMH p-value of 0.09925) had the same allele more frequent in
cases compared to controls, both within each strata (Sardinia and
continental Italy samples) and in the Talana cohort. Therefore,
when considering the distantly related cases and controls from
Talana as an additional strata in a merged dataset, evidence for
association in the region increased for all SNPs with the highest
evidence at rs12665174 (CMH p-value=0.00085). When analyz-
ing the continental Italy and Sardinian samples separately,
significant evidence for association was observed only in the
Sardinian sample, with the highest evidence at rs12665174 (p-
value=0.00502). When looking at the results obtained in the
chromosome 6 region with ROADTRIPS in the whole Talana
sample (Table S5), two additional SNPs showed nominal
significance in the LRRC16 region (rs9461102, located upstream
of LRRC16, and rs880226, located in an intron of the gene), and
one additional SNP showed a Rx p-value of 0.015627 at SLC17A1.
None of these SNPs showed evidence for association in the
replication set.
No other SNP identified in the initial study showed nominal
significance in the merged replication sample, but two SNPs
showed evidence for association in specific sub-samples:
rs11125301 located in an intron of NRXN1 on chromosome 2
was associated in the Italian sample only, and with a different
allele more frequent in cases compared to Talana; and rs12707927
on chromosome 8, that provided the highest evidence in the initial
study, and for which a different allele was associated only at a
nominal level in the Sardinian replication set (p-value=0.02260),
but with allele frequencies in cases and controls in the opposite
direction compared to Talana. For this SNP, in the analysis with
ROADTRIPS without considering the unknown population
controls, the RM and the Rx tests were both tagged with a warning
message due to the low MAF of the SNP, and were less significant
than in the initial scan RM p-value=0.00020 and Rx p-
value=0.00079.
On chromosome 10 only one SNP (rs826460) showed marginal
evidence for Rx in the flanking 5UTR region of ADAMTS14 in the
whole Talana sample with ROADTRIPS, whereas none of the
replication sets, nor the merged sample showed any evidence in
this region.
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PLoS Genetics | www.plosgenetics.org 11 January 2011 | Volume 7 | Issue 1 | e1001281Finally, in the initial scan, we identified a missense variant of the
CCDC157 gene, located on chromosome 22, whose frequency
estimated with BLUE was increased in affected cases (12.5%),
compared to either unaffected controls (5.0%) or population
controls (2.2%). The population control frequency is comparable
to the 2% frequency reported in the literature. This variant is too
rare to be identified in the relatively small replication set, and we
did observed any significant results, nor in the merged Italian
samples, not considering the two distinct geographical origins.
Discussion
In the present case-control GWAS including 73 stones formers
and 92 controls, all related to each other, and deriving from an
isolated Sardinian village, we identified different SNPs that showed
suggestive associations with UAN.
We applied a recently proposed method [20], ROADTRIPS,
that allows for the analysis of the complex type of data we have,
and we showed the improvement of the method in this founder
population over previously proposed methods implemented in the
MQLS software [18]. Indeed, providing the pair-wise kinship for
all pairs of cases and controls was not sufficient to control for
spurious association in our dataset using the MQLS test, as
additional structure was still present. The statistics implemented
in the MQLS software do not use an empirical structure matrix,
and, in the presence of additional cryptic relatedness or unknown
population structure, we observed inflated type 1 error. The
remaining population structure was accounted for in the RM test
implemented in the ROADTRIPS software by using an empirical
covariance matrix calculated using genome-wide data, while also
incorporating known genealogical information about the cases and
controls into the analysis. In contrast, both x
2 corrected statistics
(either corrected on pedigree or on genome data) showed similar
results, indicating that with a sufficiently well-characterized
genealogy data, the corrected x
2 test as implemented in the
MQLS software shows less inflation of type 1 errors over the
genome.
A deviation from the x
2 null distribution was observed
throughout the genome for both RM and MQLS for SNPs with
rarer alleles (MAF,0.1), which is an artifact of the small number
of samples in our study. Furthermore, we observed that for a
number of SNPs, the difference between RM and Rx was largely
being driven by the complex pedigree structure in the sample and
the small number of founders (see Text S2). For samples like the
Talana sample (as well as samples from founder populations like
the Hutterites) with only a small number of founders, it actually is
not clear at this time if a reasonable assessment of p-values can be
obtained in the extreme tail of the x
2 distribution (e.g., genome-
wide significance p-values ,1E-8), and this is future research to be
conducted.
A small sample is expected and unavoidable when focusing on
small, isolated villages like Talana with only 1,200 inhabitants.
Nevertheless,we wereable to identify suggestive candidate genes for
UAN in the initial GWAS, and to validate some of them in an
independent Italian sample of well characterize cases and controls.
Based on the associated SNPs in the initial scan, and their tagged
SNPs (basing on LD pattern in Talana), we identified candidate
genes on 2q33.3, 6p22.2–p21.3 and 10q22.1, that were particularly
interesting for UAN due to their physiological function. These
regions were also investigated in the independent samples by typing
additional tSNPs. Since the geographical origin of the replication
samples were either continental Italy or Sardinia, we considered
these two distinct groups in the statistical analysis using the CMH
test and tested the homogeneity of odds ratio by the BD test.
The 6p22.2 region contains the LRRC16A, SLC17A1, SLC17A4
genes, and was identified in the initial scan with a significance at
LRRC16A of Rx p-value=0.00863, and RM p-value=0.00306, at
SLC17A1 of Rx p-value=0.01048, and at SLC17A4 for RM p-
value=0.00354 at a nonsense SNP (rs2328894). Interesting, Kolz
and colleagues [29], in a meta-analysis of 14 GWAs including a
total of 28,141 participants, identified the same genes (except
SLC17A4) significantly associated with serum UA levels. There-
fore, peak SNPs in the region (Table S3) and additional 16 tSNPs
for LRRC16A and 6 tSNPs for SLC17A4-SLC17A1 were typed in
the replication set. Interestingly, different SNPs showed significant
association in the upstream and intronic regions of the LRRC16
gene in the merged replication sample, with the highest evidence
at rs12665174 (CMH p-value=0.00146). Most of the associated
SNPs in the region showed the same allele more frequent in cases
compared to controls, both within each strata (Sardinia and Italy
samples) and in the Talana cohort. Therefore, when considering
the distantly related cases and controls from Talana as an
additional strata in a merged sample, evidence for association in
the region increased with the highest evidence of CMH p-
value=0.00085 at rs12665174. When analyzing the Italian and
Sardinian samples separately, significant evidence for association
was observed only in the Sardinian sample, with the highest
evidence at rs12665174 (p-value=0.00502). When looking at the
results obtained in the chromosome 6 region with ROADTRIPS
in the whole Talana sample (Table S5), 2 additional SNPs showed
nominal significance in the LRRC16 region (rs9461102, located in
the upstream region of LRRC16, and rs880226, located in an
intron of the gene), and one additional SNP showed a Rx p-value
of 0.01563 at rs1165208, located in the intronic region of SLC17A1
(Table S5). None of these SNPs showed evidence for association in
the replication set, and no association was observed in the
replication set in the SLC17A4-SLC17A1 region.
The LRRC16A gene is, for the larger part, located in an LD
block encompassing also SCGN. In this study the coverage
obtained by adding tSNPs in this region was only 51% of the
total variation with an r
2 of at least 0.8, therefore further studies
are needed to validate the involvement of these genes to UAN.
On 2q33.3, different SNPs showed association in the initial
scan, with a peak at rs2359681 identified with both Rx and RM (p-
value=0.00008 and p-value=0.00254, respectively). The SNP is
located in an intron of DYTN, and it is in LD with other associated
SNPs located in the nearby ADAM23 gene, for which suggestive
association is observed (Figure 3 and Table S2). In the replication
set no significant association was observed when considering the
Italian and Sardinia samples together, but nominal significance
was obtained at different SNPs located in the introns of ADAM23,
with the highest evidence at rs11891267 (p-value of 0.02732) in the
Italian sample alone. The allele frequencies were oppositely
distributed in cases and controls compared to Talana, suggesting
that putative causal variant/s at the gene implicated in UAN
etiology are in LD with different alleles at the SNPs examined. In
the whole Talana sample (Table S5) two tSNPs intronic to
ADAM23 (rs1025077 and rs3755224, Rx p-value=0.01884, and p-
value=0.00069, respectively) and a SNP in the intron region of
DYTN (rs2163033, Rx p-value=0.00818) were additionally found
to be associated in the replication study.
The other interesting region identified in the initial study and
investigated further in the replication set was on 10q22.1, with the
highest association evidence observed in the initial study at the
ADAMTS14 gene. (Rx p-value=0.00003; RM p-value=0.00022).
Two other genes were found to be associated in the region on 10q,
namely LRRC20 and UNC5B (most significant RM p-val-
ue=0.00552, and RM p-value=0.00034, respectively). Interest-
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the critical region identified through linkage analysis in Talana
[14]. In the previous study we performed a genome-wide linkage
search in 14 closely-related affected individuals using 382
microsatellites, and followed up suggestive regions on 37
individuals more distantly-related affecteds. The original linkage
region spanned approximately 9 Mb, with the second highest peak
at D10S537 (position ,72,065 kb), located in the upstream region
of ADAMTS14. In the replication set we did not observe any signal
of association in either the ADAMTS14 region or in the UNC5B
region, although by typing additional tSNPs. In the Talana sample
a SNP located in the upstream region of ADAMTS14 showed
marginal evidence of association (Rx p-value=0.04647 at
rs826460, Table S5), but the SNPs that showed association in
the original scan when also including the unknown phenotype
controls in the analysis, were not found to be significantly
associated in the replication study. Further analyses are needed
to evaluate the role of this region in UAN etiology.
Among the remaining top SNPs identified in the initial GWAS
only one showed marginal evidence for association in a specific
sub-sample: rs11125301 located in an intron of NRXN1 on
chromosome 2 was only found to be associated in the Italian
sample and with a different allele that is more frequent in cases
compared to the Talana sample.
In conclusion, we obtained evidence for association to UAN for
some interesting genes in this study, whereas further investigation
is needed to validate the involvement of other genes/regions
identified in the initial GWAS. In particular, LRRC16A, already
associated to serum UA levels from previous studies, encodes for
CARMIL protein, an inhibitor of actin capping protein (CP) and
has profound effects on cell behavior. Removal of CP may be a
means to harness actin polymerization for processes such as cell
movement and endocytosis and plays important roles in
intracellular transport (the movement of vesicles and organelles).
It is interesting that this protein showed the highest expression in
kidney and other epithelial tissues [30]. The mechanism by which
variants at this gene regulate UA remains unclear. We can
envisage that this gene may be involved with the kidney, for
example, in podocytes that are glomerular cells with an actin-
based contractile apparatus and they are insulin sensitive [31]. The
insulin response of the podocytes occurs via the facilitative glucose
transporters GLUT1 and GLUT4, and this process is dependent
on the filamentous actin cytoskeleton [32]. Insulin responsiveness
in this key structural component of the glomerular filtration
barrier may have a central role in the establishment of states of
insulin resistance. Different studies have emphasized the increasing
importance of insulin resistance in the pathogenesis of UA stones
and insulin resistance is strongly correlated with low urine pH
[33]. Numerous epidemiologic studies have shown a significant
association between nephrolithiasis, obesity, glucose intolerance,
type 2 diabetes mellitus, hypertension and chronic kidney disease
[10,34–37]. There are likely still many unrecognized renal
manifestations of the metabolic syndrome. UAN, secondary to
low urine pH, might only be the tip of the iceberg. Nevertheless,
UA stone formers may have yet undisclosed mechanisms leading
to unduly low urinary pH that are not entirely accounted for by
insulin resistance [33]. Similarly, we can envisage that the F-actin
reorganization is important also in tubular cells of kidney for
proteins sorting directly involved in metabolism of UA. For the
different endophenotypes we examined (Table S6), we observed
normal serum parameters and not significant differences between
cases and controls (after correcting for age and sex). Indeed in
Talana we observed a general low urinary pH (Figure S3),
significantly lower than the distribution in the general population
(95%CI=[5.4;5.7]), that could explain the high proportion of
UAN cases among renal stones formers.
The ADAM23 gene, for which nominal significance was
observed in the Italian replication sample, encodes a member of
the ADAM (a disintegrin and metalloprotease domain) family.
ADAMs are membrane-anchored cell surface proteins with
putative roles in cell–cell and/or cell–matrix interactions and in
protease activities [38]. Members of this family have a unique
structural organization including metalloprotease, desintegrin,
cystein-rich, epidermal growth factor-like, transmembrane and
cytoplasmatic domains [38]. The available data indicate that three
of the ADAM family members are expressed at high levels in
normal brain (ADAMs 11, 22, and 23) while other members are
either expressed in the testis or are ubiquitous. More recently Ru
et al. [39] detected the ADAM23 protein in Human urine samples.
ADAM23 exhibits the typical structure of the ADAM family
members; however, the metalloproteinase domain is inactive,
suggesting that it is exclusively involved in cell adhesion. The
disintegrin and cysteine-rich domain of ADAMs have been shown
to interact with cell adhesion molecules including the receptors of
the extracellular matrix, integrins [40], as well as proteoglycans
(e.g.syndecans) [41]. It is interesting that the proteoglycans (GAGs)
are inhibitors of crystallization and appear to be involved in kidney
stone formation. In a previous study we showed that the lower
excretion of GAGs in stone formers could impair their inhibitory
activity on UA stone formation, and, as a consequence, it may
represent a risk factor for this form of urolithiasis [42].
Furthermore, a proteoglycan like Syndecan-4 was up-regulated
in proliferative renal disease and mice deficient in syndecan-4 were
more susceptible to k-carrageenan induced renal damage
indicating that syndecan-4 plays an important role in renal
diseases [43]. Finally, Hwang et al. [44] reported a strong
association with ADAM23 for urinary albumin excretion, that is a
marker of kidney function.
Due to the small sample of affected subjects used in the initial
scan, statistical power was consequently relatively low in this study,
and indeed the significance of the evidence for association with the
identified SNPs is lower than genome-wide significance consider-
ing Bonferroni correction. On the other hand, we have the
advantage of using a homogenous cohort of individuals, sharing a
very similar life style and dietary habits, and with an increased
genetic homogeneity, as a consequence of a strong founder effect
and of genetic drift deriving from isolation that endured for
centuries. A consequence of association studies in founder
populations can be lower statistical power due to having small
sample sizes. A compelling advantage, however, for such samples
is increased homogeneity in terms of both environmental and
genetic factors involved in disease etiology, which can ultimately
improve the power to detect association. Although our sample was
relatively small, we were nevertheless able to identify different
candidate genes with a potential role in UAN, and to provide
evidence for association in an independent sample for the gene
LRRC16A on 6p, already found to be associated to serum UA
levels in a large meta-analysis of 14 GWAS and possibly for
ADAM23 on 2q.
To our knowledge this GWAS is the first one carried out for
UAN. It is also the first application of ROADTRIPS to a founder
population. The original application of ROADTRIPS [20] was to
both simulated and real data in samples from outbred populations.
The sample sizes of the cases and/or the controls in the previous
applications used to evaluate the method were also more than five
times the sample we analyzed in this study. We were able to
evaluate the performance of the method using real data from a
small sample in a genetic isolate, which likely has different
GWAS for Nephrolithiasis
PLoS Genetics | www.plosgenetics.org 13 January 2011 | Volume 7 | Issue 1 | e1001281properties and complexities than the data sets previously used to
evaluate the type 1 error and power of ROADTRIPS.
Supporting Information
Figure S1 MAF corresponding to warnings in ROADTRIPS.
Box-plots for the MAF (naı ¨ve estimates) for the statistics tagged by
a warning message for each specific case/control cohort. Box-plots
are shown for the 500K and 50K sets separately, as a different
number of individuals were genotyped for the two sets (829 and
514 subjects, respectively).
Found at: doi:10.1371/journal.pgen.1001281.s001 (0.08 MB TIF)
Figure S2 Q-Q plots for RM and Rx stratified by warning
messages in ROADTRIPS. For the Rx statistic warning messages
entailing the case, controls or both samples were considered
together.
Found at: doi:10.1371/journal.pgen.1001281.s002 (0.06 MB TIF)
Figure S3 pH distribution in Talana (N=218). Red bars
indicate pH in affected cases (N=43). The red line indicates the
pH level (=6) in the general population.
Found at: doi:10.1371/journal.pgen.1001281.s003 (0.20 MB TIF)
Table S1 Tagged regions for the replication study and resulting
coverage based on r2 .0.8.
Found at: doi:10.1371/journal.pgen.1001281.s004 (0.03 MB
DOC)
Table S2 Region 2q.
Found at: doi:10.1371/journal.pgen.1001281.s005 (0.07 MB
DOC)
Table S3 Region 6p.
Found at: doi:10.1371/journal.pgen.1001281.s006 (0.09 MB
DOC)
Table S4 Region 10q.
Found at: doi:10.1371/journal.pgen.1001281.s007 (0.11 MB
DOC)
Table S5 Results obtained with ROADTRIPS for the whole
Talana sample in the replication study for the 96 SNPs.
Found at: doi:10.1371/journal.pgen.1001281.s008 (0.10 MB
DOC)
Table S6 Phenotypic characteristics of the case/control sample
used in this analysis.
Found at: doi:10.1371/journal.pgen.1001281.s009 (0.04 MB
DOC)
Text S1 Quality control of genome-wide SNP data in Talana.
Found at: doi:10.1371/journal.pgen.1001281.s010 (0.31 MB
DOC)
Text S2 Investigating SNPs in the Talana sample.
Found at: doi:10.1371/journal.pgen.1001281.s011 (0.97 MB PDF)
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